Broad Portfolio Akoya's comprehensive suite of spatial phenotyping solutions (PhenoCode Panels, PhenoCycler, PhenoImager Fusion/HT) supports researchers from discovery to clinical studies, enabling cross-sell opportunities across product lines and upgrading customers to higher-tier systems.

Oncology Focus Recent activity shows a strong oncology focus, with ADC Breast Cancer assay expansion and Immunoprint melanoma collaboration; opportunities to target oncology biotech and pharma with IO60 panels and multiplex immunofluorescent platforms for patient stratification and companion diagnostics.

Strategic Partnerships Strategic licensing and collaboration programs, including exclusive NeraCare Immunoprint license and the HistoWiz PSP partnership, indicate a viable path for channel sales, co-development deals, and accelerated adoption through partner ecosystems.

Market Momentum The spatial biology market is accelerating as researchers seek contextual tissue insights; Akoya's IO60 Discovery line and continuous product updates position the company to capitalize on demand for spatial analytics, enabling upsell/expansion into existing customers and new accounts.

Global Expansion Evidence of EU engagement through NeraCare collaboration and a global license scenario suggests expansion opportunities in Europe and other regions; target pharma, academics, and CROs with regional demonstrations, local support, and partner networks.